He said that the vaccine has been shown to be "really quite remarkably protective" in studies on monkeys at the National Institutes of Health in the U.S. Ebola drugs are in the works Researchers are under tremendous pressure to develop a vaccine, as over 3,400 people have died in West Africa and a Spanish nurse's assistant was confirmed on Monday to be the first person to have contracted the virus outside of Africa. Your Ebola questions answered There is little worry, he said, about administering a vaccine to humans in a phase one trial, as he said will begin this week in West Africa. " "And we're now trying to proceed so quickly that if things go well, by the end of the year, this vaccine might actually be being used in the three affected countries in West Africa." But even if researchers are able to make enough vaccine, and have data showing that it is safe for use in humans and produces good immune responses, Hill said that they will would not know that "it actually works. "Once you've shown safety in those individuals, do you go on to deploy the vaccine in a very large population -- ideally of health-care workers who are at greatest risk -- without knowing that the vaccine actually works?" "Or instead, do you wait several months -- maybe six months, maybe a year -- to prove absolutely that the vaccine has a certain efficacy and then start thinking about deploying it widely?" "